BMC Pediatr
- ZHU J, Cheng W, Xu Y, Guo Y, et al
Two cases of small bowel necrosis due to intussusception secondary to abnormal
proliferation of intestinal Peyer's patches in infants after MMR vaccination.
BMC Pediatr. 2024;24:147.
- GETA M, Yizengaw E, Manyazewal T
Hepatitis B vaccine effectiveness among vaccinated children in Africa: a
systematic review and meta-analysis.
BMC Pediatr. 2024;24:145.
- SAYINZOGA F, Hirschhorn LR, Ntawukuriryayo JT, Beyer C, et al
Understanding rapid implementation from discovery to scale: Rwanda's
implementation of rotavirus vaccines and PMTCT in the quest to reduce under-5
mortality.
BMC Pediatr. 2024;23.
BMJ
- WISE J
Covid-19 taskforce called for a new national vaccine agency to prepare for future
pandemics.
BMJ. 2024;384:q534.
- TAYLOR L
Dengue fever: Brazil rushes out vaccine as climate change fuels unprecedented
surge.
BMJ. 2024;384:q483.
- WISE J
Covid-19: Two rare vaccine side effects detected in large global study.
BMJ. 2024;384:q488.
Clin Infect Dis
- SHAH MM, Joyce B, Plumb ID, Sahakian S, et al
Combined protection of vaccination and nirmatrelvir-ritonavir against
hospitalization in adults with COVID-19.
Clin Infect Dis. 2024 Feb 27:ciae105. doi: 10.1093.
J Gen Virol
- RAO S, Erku D, Mahalingam S, Taylor A, et al
Immunogenicity, safety and duration of protection afforded by chikungunya virus
vaccines undergoing human clinical trials.
J Gen Virol. 2024;105.
J Infect Dis
- CAO Y, Hayashi CTH, Kumar N
A novel ex vivo assay to evaluate functional effectiveness of Plasmodium vivax
transmission blocking vaccine using Pvs25 transgenic P. berghei.
J Infect Dis. 2024 Feb 26:jiae102. doi: 10.1093.
- WANTUCH PL, Knoot CJ, Robinson LS, Vinogradov E, et al
A heptavalent O-antigen bioconjugate vaccine exhibits differential functional
antibody responses against diverse Klebsiella pneumoniae isolates.
J Infect Dis. 2024 Feb 24:jiae097. doi: 10.1093.
- DZIADULA J, Sabbaj S, Gupta K, Cutter G, et al
Interferon-Gamma Responses to Chlamydia trachomatis Vaccine Candidate Proteins in
Chlamydia-Infected Women with Different Chlamydia Outcomes.
J Infect Dis. 2024 Feb 23:jiae092. doi: 10.1093.
J Virol
- GEORGANA I, Scutts SR, Gao C, Lu Y, et al
Filamin B restricts vaccinia virus spread and is targeted by vaccinia virus
protein C4.
J Virol. 2024 Feb 27:e0148523. doi: 10.1128/jvi.01485.
JAMA
- ANDERSSON NW, Thiesson EM, Hviid A
Adverse Events After XBB.1.5-Containing COVID-19 mRNA Vaccines.
JAMA. 2024 Feb 26:e241036. doi: 10.1001/jama.2024.1036.
- JAMIESON KH, Johnson KB, Cappola AR
Misinformation and the Vaccine Adverse Event Reporting System.
JAMA. 2024 Feb 26. doi: 10.1001/jama.2024.1757.
Lancet
- COOPER LV, Blake IM
First Africa-based clinical trial for novel type 2 oral poliovirus vaccine.
Lancet. 2024 Feb 22:S0140-6736(24)00053-9. doi: 10.1016/S0140-6736(24)00053.
- OCHOGE M, Futa AC, Umesi A, Affleck L, et al
Safety of the novel oral poliovirus vaccine type 2 (nOPV2) in infants and young
children aged 1 to <5 years and lot-to-lot consistency of the immune response to
nOPV2 in infants in The Gambia: a phase 3, double-blind, randomised controlled
trial.
Lancet. 2024 Feb 22:S0140-6736(23)02844-1. doi: 10.1016/S0140-6736(23)02844.
MMWR Morb Mortal Wkly Rep
- ZHU S, Quint J, Leon TM, Sun M, et al
Interim Influenza Vaccine Effectiveness Against Laboratory-Confirmed Influenza -
California, October 2023-January 2024.
MMWR Morb Mortal Wkly Rep. 2024;73:175-179.
- DECUIR J, Payne AB, Self WH, Rowley EAK, et al
Interim Effectiveness of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccines
Against COVID-19-Associated Emergency Department and Urgent Care Encounters and
Hospitalization Among Immunocompetent Adults Aged >/=18 Years - VISION and IVY
Networks,
MMWR Morb Mortal Wkly Rep. 2024;73:180-188.
- FRUTOS AM, Price AM, Harker E, Reeves EL, et al
Interim Estimates of 2023-24 Seasonal Influenza Vaccine Effectiveness - United
States.
MMWR Morb Mortal Wkly Rep. 2024;73:168-174.
N Engl J Med
- MONTO AS, Zambon M, Weir JP
The End of B/Yamagata Influenza Transmission - Transitioning from Quadrivalent
Vaccines.
N Engl J Med. 2024 Feb 28. doi: 10.1056/NEJMp2314801.
Nat Med
- PERETTI-WATEL P, Verger P, Ward JK
To understand mRNA vaccine hesitancy, stop calling the public anti-science.
Nat Med. 2024 Feb 27. doi: 10.1038/s41591-024-02816.
Pediatrics
- O'LEARY ST, Opel DJ, Cataldi JR, Hackell JM, et al
Strategies for Improving Vaccine Communication and Uptake.
Pediatrics. 2024;153:e2023065483.
PLoS Comput Biol
- VALEGA-MACKENZIE W, Rodriguez Messan M, Yogurtcu ON, Nukala U, et al
Dose optimization of an adjuvanted peptide-based personalized neoantigen melanoma
vaccine.
PLoS Comput Biol. 2024;20:e1011247.
PLoS One
- WU S, Li Y, Baral S, Mishra S, et al
Protection of prior SARS-CoV-2 infection, COVID-19 boosters, and hybrid immunity
against Omicron severe illness: A population-based cohort study of five million
residents in Canada.
PLoS One. 2024;19:e0299304.
- BASHIR IM, Al-Waleedi AA, Al-Shaibani SM, Rajamanar M, et al
Strengthening laboratories in response to outbreaks in humanitarian emergencies
and conflict settings: Results, challenges and lessons from expanding PCR
diagnostic capacities for COVID-19 testing in Yemen.
PLoS One. 2024;19:e0298603.
- DIAS E, Diniz AMA, Souto GR, Guerra HL, et al
Predicting COVID-19 cases in Belo Horizonte-Brazil taking into account mobility
and vaccination issues.
PLoS One. 2024;19:e0269515.
- KONLAN MY, Mahama F, Abubakari BB, Konka P, et al
Predictors of vaccination card retention in Tamale Metropolis, Ghana.
PLoS One. 2024;19:e0292765.
-
Retraction: Properly Folded Bacterially Expressed H1N1 Hemagglutinin Globular
Head and Ectodomain Vaccines Protect Ferrets against H1N1 Pandemic Influenza
Virus.
PLoS One. 2024;19:e0300096.
- HOU Y, Bidkhori H
Multi-feature SEIR model for epidemic analysis and vaccine prioritization.
PLoS One. 2024;19:e0298932.
- ABER JO, Bongomin F, Opio SL, Ochola E, et al
Hepatitis B vaccine uptake and associated factors among adults of Gulu city in
Northern Uganda: A community-based cross-sectional study.
PLoS One. 2024;19:e0297617.
Proc Natl Acad Sci U S A
- CHANG S, Shin KS, Park B, Park S, et al
Strategy to develop broadly effective multivalent COVID-19 vaccines against
emerging variants based on Ad5/35 platform.
Proc Natl Acad Sci U S A. 2024;121:e2313681121.
Science
- PAWAR P
World's cholera vaccine stash is empty-but relief is on its way.
Science. 2024;383:939-940.
Vaccine
- LEVIN MJ, Ginde AA, Schmid DS, Lang N, et al
Effect of high dose vitamin D supplementation on subsequent immune responses to
administration of the live herpes zoster vaccine to long-term care residents.
Vaccine. 2024 Feb 28:S0264-410X(24)00214-7. doi: 10.1016/j.vaccine.2024.
- MARINDA E, Mathentamo Q, Coulson N, Parker S, et al
Impact evaluation of a youth led intervention to increase COVID-19 vaccine uptake
in Kwazulu-Natal, South Africa.
Vaccine. 2024 Feb 28:S0264-410X(24)00211-1. doi: 10.1016/j.vaccine.2024.
- OMAR ALI S, Dessart C, Parikh R
Co-administration of the adjuvanted recombinant zoster vaccine with other adult
vaccines: An overview.
Vaccine. 2024 Feb 28:S0264-410X(24)00194-4. doi: 10.1016/j.vaccine.2024.
- GUO J, Chen X, Guo Y, Liu M, et al
Real-world effectiveness of seasonal influenza vaccination and age as effect
modifier: A systematic review, meta-analysis and meta-regression of test-negative
design studies.
Vaccine. 2024 Feb 28:S0264-410X(24)00218-4. doi: 10.1016/j.vaccine.2024.
- ZHOU W, Guo X, Lu J, Lu X, et al
Parental willingness to accept and pay human papillomavirus vaccine for boys aged
9-14 in a metropolis area of China: Evidence for developing a vaccination
strategy.
Vaccine. 2024 Feb 28:S0264-410X(24)00253-6. doi: 10.1016/j.vaccine.2024.
- YADEGARYNIA D, Keyvanfar A, Keyvani H, Tehrani S, et al
Immunogenicity and safety of a quadrivalent recombinant influenza vaccine
manufactured in Iran (FluGuard) in volunteers aged 18-60 years: A double-blind,
non-inferiority, randomized controlled trial.
Vaccine. 2024 Feb 29:S0264-410X(24)00249-4. doi: 10.1016/j.vaccine.2024.
- JACKSON S, Kabir Z, Comiskey C
Retrospective cohort study exploring the impact of universal Tuberculosis (TB)
vaccination cessation on the epidemiology of paediatric TB in Ireland, 2011-2021.
Vaccine. 2024 Feb 28:S0264-410X(24)00220-2. doi: 10.1016/j.vaccine.2024.
- JABBAR F, Kadhim KA, Alhilfi RA, Chitheer A, et al
Intensification of integrated immunization services to recover routine
vaccination coverage and bring COVID-19 vaccine to the population of Iraq in
2022.
Vaccine. 2024 Feb 27:S0264-410X(24)00197-X. doi: 10.1016/j.vaccine.2024.
- PREVOT-MONSACRE P, Hamaide-Defrocourt F, Guyonvarch O, Masse S, et al
What is the relevancy of a surveillance of mumps without a systematic laboratory
confirmation in highly immunized populations? Epidemiology of suspected and
biologically confirmed mumps cases seen in general practice in France between
2014 and 2020.
Vaccine. 2024;42:1065-1070.
- DREYFUS J, Munnangi S, Bengtsson C, Correia B, et al
Background incidence rates of health outcomes in populations at risk for Lyme
disease using US administrative claims data.
Vaccine. 2024;42:1094-1107.
- YANG XY, Liu T, Jiang SC, Zhang ZW, et al
Antibodies against SARS-CoV-2 non-structural protein 3 cross-react with human
muscle cells and neuroglial cells.
Vaccine. 2024;42:1259-1267.
- SHETTY AN, Morgan HJ, Phuong LK, Mallard J, et al
Audiovestibular adverse events following COVID-19 vaccinations.
Vaccine. 2024 Feb 22:S0264-410X(24)00210-X. doi: 10.1016/j.vaccine.2024.
- MURPHY C, Kwan MYW, Chan ELY, Wong JSC, et al
Influenza vaccine effectiveness against hospitalizations associated with
influenza A(H3N2) in Hong Kong children aged 9 months to 17 years, June-November
2023.
Vaccine. 2024 Feb 22:S0264-410X(24)00215-9. doi: 10.1016/j.vaccine.2024.
- BIJUKCHHE SM, Gurung M, Pokhrel B, Shakya M, et al
Immune responses to typhoid conjugate vaccine in a two dose schedule among
Nepalese children <2 years of age.
Vaccine. 2024 Feb 22:S0264-410X(24)00156-7. doi: 10.1016/j.vaccine.2024.
- NEWALL AT, Nazareno AL, Muscatello DJ, Boettiger D, et al
The association between influenza vaccination uptake and influenza and
pneumonia-associated deaths in the United States.
Vaccine. 2024 Feb 24:S0264-410X(24)00113-0. doi: 10.1016/j.vaccine.2024.
- HOTEZ PJ, Bottazzi ME, Kaye PM, Lee BY, et al
Neglected tropical disease vaccines: hookworm, leishmaniasis, and
schistosomiasis.
Vaccine. 2023;41 Suppl 2.
- FLANDES X, Hansen CA, Palani S, Abbas K, et al
Vaccine value profile for Chikungunya.
Vaccine. 2023 Nov 7:S0264-410X(23)00915-5. doi: 10.1016/j.vaccine.2023.
- KRISTINSDOTTIR I, Haraldsson A, Thors V
Influenza vaccination in pregnant women in Iceland 2010-2020 and the burden of
influenza in pregnant women and their infants.
Vaccine. 2024 Feb 26:S0264-410X(24)00205-6. doi: 10.1016/j.vaccine.2024.
- TOLENTINO JUNIOR DS, Vasconcelos Marques MS, de Oliveira RC
Rabies vaccination of the Maxakali indigenous population.
Vaccine. 2024 Feb 26:S0264-410X(23)01542-6. doi: 10.1016/j.vaccine.2023.
- KEGELE LIGNANI L, de Vasconcellos Carvalhaes de Oliveira R, Matos Dos Santos E, Antonio Bastos Camacho L, et al
Neutralizing antibody titers against D8 genotype and persistence of measles
humoral and cell-mediated immunity eight years after the first dose of measles,
mumps, and rubella vaccine in Brazilian children.
Vaccine. 2024 Feb 26:S0264-410X(24)00219-6. doi: 10.1016/j.vaccine.2024.
- MUNDO ORTIZ A, Nasri B
Socio-demographic determinants of COVID-19 vaccine uptake in Ontario: Exploring
differences across the Health Region model.
Vaccine. 2024 Feb 26:S0264-410X(24)00204-4. doi: 10.1016/j.vaccine.2024.
- GIDENGIL C, Scherer AM, Parker AM, Gedlinske A, et al
Lyme disease vaccine attitudes and intentions among parents of children aged 5-18
years in the United States.
Vaccine. 2024 Feb 27:S0264-410X(24)00105-1. doi: 10.1016/j.vaccine.2024.
- TANAKA M, Okubo R, Hoshi SL, Kondo M, et al
Cost-effectiveness analysis of pertussis booster vaccination for adolescents in
Japan.
Vaccine. 2024 Feb 27:S0264-410X(24)00199-3. doi: 10.1016/j.vaccine.2024.
Free Medical Abstracts
Privacy Policy
Sponsors
Share
© Amedeo 1997-2016